Tau Global 2026, held in Washington D.C., brought together researchers, clinicians, advocates, industry leaders, nonprofit organizations, and people living with tau-related disease for two days of scientific exchange focused on one shared goal: accelerating progress toward transformative treatments for tauopathies.

Hosted in partnership with the Alzheimer’s Association, CurePSP, and the Rainwater Charitable Foundation, this year’s meeting reflected both the remarkable momentum and growing sophistication of the field. Tau Global 2026 convened at a pivotal moment for tau therapeutics, coinciding with the release and active discussion of topline results from Biogen’s Phase 2 CELIA study evaluating the tau-targeting ASO diranersen (BIIB080) on the meeting’s opening day. While the announcement reflected both the promise and ongoing complexity of tau-directed therapeutic development, it also reinforced the urgency driving many of the conversations that followed throughout the conference. Across the meeting, discussions spanned biomarker development, therapeutic strategies, genetics, neuroinflammation, systems biology, and the evolving understanding of tau itself—while remaining firmly grounded in the experiences of patients and families navigating these devastating diseases.

One of the clearest themes emerging across Tau Global 2026 was the increasing recognition that tauopathies are far more biologically complex and heterogeneous than previously appreciated. Discussions explored how tau structure, localization, and assembly state may influence disease progression and neuronal dysfunction in distinct ways, reinforcing growing evidence that not all tau species are equally toxic. At the same time, conversations expanded beyond tau aggregation alone to examine how mitochondrial dysfunction, neuroinflammation, vascular pathology, blood-brain barrier regulation, extracellular vesicle signaling, and hypoxia-related pathways may all contribute to neurodegeneration. Genetics-focused sessions further emphasized the importance of expanding representation and global collaboration across the field, highlighting how most known tau-associated datasets remain derived from populations of European ancestry. This underscores the need for broader cross-ancestry genomic analyses to improve scientific understanding and therapeutic discovery across diverse populations.

Discussions around biomarkers reflected this same shift toward precision. Sessions highlighted advances in seed amplification assays (SAA), blood-based biomarkers, and next-generation tau PET imaging approaches aimed at detecting disease earlier and distinguishing among diverse tauopathies with greater specificity. Several talks underscored the need for disease- and isoform-specific imaging ligands, including separate approaches for 3R and 4R tau pathology, alongside efforts to improve patient accessibility through shorter imaging protocols.

Therapeutic development also remained a central focus, with presentations exploring a rapidly diversifying landscape that now includes antibodies, antisense oligonucleotides (ASOs), siRNA approaches, splice-modulating therapies, and advanced blood-brain barrier delivery technologies. A recurring theme across these sessions was that future progress will likely depend not only on the therapies themselves, but on continued refinement of biomarkers, clinical trial design, patient selection, and potentially combination therapeutic approaches capable of targeting multiple aspects of disease biology simultaneously.

One of the meeting’s most closely watched presentations came from Günter Höglinger, who shared results from the Phase 1 dose-escalation study of NIO752, an ASO targeting MAPT mRNA in PSP. The study demonstrated acceptable safety and tolerability alongside evidence of target engagement, including sustained reductions in CSF total tau and p-tau181 in higher-dose cohorts. The findings support advancement into the ongoing Phase 3 PRESERVE clinical trial and represent an important milestone for tau-targeted therapeutics.

The meeting also celebrated scientific leadership across generations through the Rainwater Prize program. Dr. Marc Aurel Busche received the 2026 Rainwater Prize for Innovative Early-Career Scientist for his work exploring how distinct tau species influence neuronal dysfunction and cognitive decline. Drs. Dennis Dickson and Melissa Murray received the Rainwater Prize for Outstanding Innovation in Neurodegenerative Research in recognition of their collaborative contributions to neuropathology and the understanding of tau-related disease.

Tau Global 2026 concluded with a forward-looking panel discussion focused on a “Vision to 2030” for tau-based research. Themes included breaking down research silos with intentional collaboration and coordinated data sharing.  The panelists also expressed the urgent need for a scalable biomarker and clinical trial infrastructure. Meaningful integration of the patient voice across every stage of research and clinical development carried throughout the conversation. A live graphical recording captured many of the meeting’s recurring ideas, including bold “moonshot” thinking, preventative approaches, and the importance of building shared infrastructure across the tau research ecosystem.

Across two days of discussion, Tau Global 2026 reflected a field entering a new phase—one increasingly defined by precision biomarkers, integrated systems biology, translational rigor, and growing collaboration across academia, industry, philanthropy, government, and patient communities. While significant challenges remain, the collective momentum across the tau research community continues to move the field closer toward effective therapies for patients and families affected by tauopathies.